drugset / Trial / NCT02176018
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and effectiveness of daily dextromethorphan/quinidine (Nuedexta) in reducing the frequency and progression of episodic migraine.
Timeline
- Start
- 2014-08
- Primary completion
- 2017-02
- Completion
- 2017-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dextromethorphan | Unknown | 20 mg | Oral |
| Comparator | Quinidine | Small molecule | 10 mg | Oral |